吉非替尼治疗伴有表皮生长因子受体基因突变的非小细胞肺癌的研究进展

Progress in search for gefitinib in the treatment of non-small cell lung cancer with gene mutation of epidermal growth factor receptor

肺癌为恶性肿瘤死亡首位原因,而非小细胞肺癌(NSCLC)约占其中的80%。NSCLC中85%以上属中晚期肺癌,5年生存率仅有15%。吉非替尼主要用于晚期非小细胞肺癌(NSCLC)患者经化疗后进展的单用疗法,2003年5月经FDA批准上市。本文对其作用机制、药代动力学进行了概述。

Lung cancer is the first death reason for malignant tumors, and non -small cell lung cancer （NSCLC） accounted for about 80% of them. More than 85% of NSCLC lung cancers are in middle -late stage, and the 5 years survival rate is merely about 15%. Gefitinib, which was approved by FDA to come into the market in May 2003, is mainly used for the late non - small cell lung cancer （NSCLC） patients who get progression after chemotherapy . This article involves the mechanism of its action and pharmacokinetics of gefitinib.